Trial of andexanet alfa in ICrH patients receiving an oral FXa inhibitor

Study identifier:18-513

ClinicalTrials.gov identifier:NCT03661528

EudraCT identifier:2018-002620-17

CTIS identifier:N/A

Study Complete

Official Title

A Randomized Clinical Trial of Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor Xa Inhibitor

Medical condition

Acute Intracranial Hemorrhage

Phase

Phase 4

Healthy volunteers

No

Study drug

andexanet alfa, Usual Care

Sex

All

Actual Enrollment

530

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 06 Jun 2019
Primary Completion Date: 27 May 2023
Study Completion Date: 09 Aug 2023

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2025 by Alexion Pharmaceuticals, Inc.

Sponsors

Alexion Pharmaceuticals, Inc.

Collaborators

-

Inclusion and exclusion criteria